<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the case of a young woman with <z:hpo ids='HP_0001268'>progressive cognitive decline</z:hpo> and <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>She showed ischemic cerebrovascular disease and proximal <z:e sem="disease" ids="C0085642" disease_type="Disease or Syndrome" abbrv="">livedo racemosa</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> (aPL) could not be detected and there were no microemboli on continuous transcranial Doppler ultrasonography monitoring </plain></SENT>
<SENT sid="3" pm="."><plain>Histology of cerebral vessels showed intimal <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> in small leptomeningeal venous vessels and micronecrosis of grey and white matter </plain></SENT>
<SENT sid="4" pm="."><plain>We subsequently made the diagnosis of aPL-negative <z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon Syndrome</z:e> (SNS) </plain></SENT>
<SENT sid="5" pm="."><plain>Anticoagulation with <z:chebi fb="8" ids="10033">warfarin</z:chebi> could not be initiated because of a drug-resistant <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> with the risk of <z:hpo ids='HP_0002527'>falls</z:hpo> and subsequent <z:mp ids='MP_0001914'>bleeding</z:mp>; immunosuppression with steroids and <z:chebi fb="2" ids="2948">azathioprine</z:chebi> was ineffective, as was initial antiplatelet therapy with <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> alone </plain></SENT>
<SENT sid="6" pm="."><plain>However, when we intensified antiplatelet therapy by combining <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> and ASS, a slowing of disease progression, as assessed by neuropsychological testing and magnetic resonance imaging, was noted on a follow-up after 6 months </plain></SENT>
<SENT sid="7" pm="."><plain>Therapeutic options in SNS in both aPL-positive and aPL-negative patients with SNS are discussed </plain></SENT>
</text></document>